Brain zaps for Alzheimer's: new study targets gut bugs to boost memory
NCT ID NCT07346794
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a non-invasive brain stimulation technique called rTMS can improve symptoms of Alzheimer's disease by regulating the 'gut-brain axis'—the link between gut bacteria and the brain. Researchers will treat 200 Alzheimer's patients with either real or sham rTMS for 4 weeks, then track their memory, thinking, and gut health for a year. Another 200 healthy volunteers will serve as a comparison group. The goal is to understand how rTMS might work through the gut-brain connection, not to cure the disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- repetitive transcranial magnetic stimulation (rTMS)
- What this could lead to
- If it works, this could point toward a non-drug treatment for Alzheimer's that improves memory and thinking by restoring balance in the gut-brain connection.
- What could go wrong
- This is an early-stage study (Phase NA) focused on understanding mechanisms, not yet proving a cure. The treatment is short-term (4 weeks), and benefits may be modest or temporary. Mild side effects like headache or scalp irritation are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 400 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Dementia Patients: Conformed to internationally recognized diagnostic criteria for dementia (e.g., DSM-5, NINCDS-ADRDA) * Diagnosed through clinical evaluation, neuropsychological scale assessments, and relevant examinations * Aged ≥50 years and residing in Nanchang, Jiangxi * With dementia-negative family history, no severe psychiatric or neurological disorders * No history of major systemic diseases. Exclusion Criteria: * Unable to cooperate with all required examinations, intervention procedures, and sample collection during the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer's disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Randomized, delayed start, double blind, parallel group, placebo controlled, multicenter study of piromelatine 20 mg in participants with mild dementia due to Alzheimer's disease
- Could brain stimulation help Alzheimer's patients think more clearly?
- Could a common blood pressure pill recharge brain cells in Alzheimer's?
- Could an HIV drug tame Alzheimer's? a trial puts it to the test
- Could a breath test reveal Parkinson's risk?
- Can a new pill slow Alzheimer's decline?